AU2013218167B2 - Aurora and FLT3 kinases modulators - Google Patents

Aurora and FLT3 kinases modulators Download PDF

Info

Publication number
AU2013218167B2
AU2013218167B2 AU2013218167A AU2013218167A AU2013218167B2 AU 2013218167 B2 AU2013218167 B2 AU 2013218167B2 AU 2013218167 A AU2013218167 A AU 2013218167A AU 2013218167 A AU2013218167 A AU 2013218167A AU 2013218167 B2 AU2013218167 B2 AU 2013218167B2
Authority
AU
Australia
Prior art keywords
compound
hydrogen
kinase
aurora
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013218167A
Other languages
English (en)
Other versions
AU2013218167A1 (en
Inventor
John Charles Reader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of AU2013218167A1 publication Critical patent/AU2013218167A1/en
Application granted granted Critical
Publication of AU2013218167B2 publication Critical patent/AU2013218167B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013218167A 2012-02-06 2013-02-04 Aurora and FLT3 kinases modulators Ceased AU2013218167B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
GB1202027.7 2012-02-06
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (2)

Publication Number Publication Date
AU2013218167A1 AU2013218167A1 (en) 2014-08-14
AU2013218167B2 true AU2013218167B2 (en) 2017-04-06

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013218167A Ceased AU2013218167B2 (en) 2012-02-06 2013-02-04 Aurora and FLT3 kinases modulators

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法
BR112020002674A2 (pt) * 2017-08-07 2020-07-28 Joint Stock Company Biocad compostos heterocíclicos inovadores como inibidores de cdk8/19
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
AU2001266505A1 (en) 2000-06-28 2002-01-08 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
ATE363276T1 (de) 2000-10-30 2007-06-15 Janssen Pharmaceutica Nv Tripeptidylpeptidase-hemmer
JP4570955B2 (ja) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
US7718676B2 (en) 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2010011375A2 (en) 2008-04-21 2010-01-28 Merck & Co., Inc. Inhibitors of janus kinases
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
KR101750125B1 (ko) * 2010-01-12 2017-06-22 에이비 사이언스 티아졸 및 옥사졸 키나제 저해제
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
SG11201404277WA (en) 2014-08-28
CA2863759A1 (en) 2013-08-15
CN104169277A (zh) 2014-11-26
GB201202027D0 (en) 2012-03-21
EP2812328B1 (en) 2015-11-18
BR112014019254A2 (enExample) 2017-06-20
JP6034880B2 (ja) 2016-11-30
AU2013218167A1 (en) 2014-08-14
KR102052780B1 (ko) 2019-12-05
US9133180B2 (en) 2015-09-15
RU2643809C2 (ru) 2018-02-06
MX338481B (es) 2016-04-19
DK2812328T3 (en) 2016-01-11
WO2013117522A1 (en) 2013-08-15
PT2812328E (pt) 2016-03-01
IL233988A (en) 2017-06-29
RU2014131784A (ru) 2016-03-27
HK1204327A1 (en) 2015-11-13
PL2812328T3 (pl) 2016-04-29
MX2014009323A (es) 2015-04-08
CN104169277B (zh) 2016-10-12
CA2863759C (en) 2020-04-14
BR112014019254B1 (pt) 2020-03-10
ES2560260T3 (es) 2016-02-18
EP2812328A1 (en) 2014-12-17
US20150018367A1 (en) 2015-01-15
BR112014019254A8 (pt) 2017-07-11
JP2015511228A (ja) 2015-04-16
KR20140128373A (ko) 2014-11-05

Similar Documents

Publication Publication Date Title
JP2022508055A (ja) サイクリン依存性キナーゼ7(cdk7)の阻害剤
KR102709127B1 (ko) Fak 억제제 및 그 약물 조합물
EP3519398B1 (en) Pyridine compound
JP7328323B2 (ja) SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物
EP2315761B1 (en) Pharmaceutical compounds
EP3423443A1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
Zhao et al. Highly selective MERTK inhibitors achieved by a single methyl group
AU2013218167B2 (en) Aurora and FLT3 kinases modulators
WO2018194520A9 (en) Small molecule inhibitors of bcl-2-associated death promoter (bad) phosphorylation
CN105050602A (zh) 作为pi3激酶抑制剂的吡啶化合物
EP4066831A1 (en) Pharmaceutical compounds
WO2025111586A1 (en) Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
HK1204327B (en) Aurora and flt3 kinases modulators
TW202412809A (zh) 包含標靶療法的抗癌組合
TW202540122A (zh) Kras-g12d之氮雜-四環氧氮呯抑制劑的多晶型物及合成方法
HK40065050A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112019022015B1 (pt) Inibidores de moléculas pequenas de fosforilação de promotor de morte associado a bcl-2 (bad)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired